AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of
AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced
cervical cancer. Dose escalation will be conducted using the modified toxicity probability
interval (mTPI) method.
Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30
mg/kg (level 1) and 50 mg/kg (level 2).